• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Slovakia Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Slovakia Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Slovakia
  • 98 pages
  • Business Monitor International

FEATURED COMPANIES

  • Biotika
  • GlaxoSmithKline
  • Local Companies
  • Multinational Companies
  • Pfizer
  • Sanofi
  • MORE

BMI View:

Slovak Prime Minister Robert Fico plans to unify the country's private and public health insurance funds into a single state-owned insurer, but there is likely to be a lengthy negotiation and a legal battle before this is realised. We do not expect either of the two private insurers - Dôvera or Dutchowned Union - will surrender their businesses without a fight, with Union in particular well-placed to oppose the move, potentially invoking EU law on protectionism. The outcome of this step towards a single insurer is broadly neutral for BMI's healthcare expenditure projections and is unlikely to have any meaningful impact until 2014 at the earliest, after which it would be negative for private healthcare providers.

Headline Expenditure Projections:

- Pharmaceuticals: EUR1.72bn (US$2.39bn) in 2011 to EUR1.65bn (US$2.10bn) in 2012; -3.8
%in local currency terms and -12.1% in US dollar terms. Local currency forecast broadly unchanged from Q412.

- Healthcare: EUR5.92bn (US$8.23bn) in 2011 to EUR6.03bn (US$7.65bn) in 2012; +1.7% in local currency terms and -7.0% in US dollar terms. Local currency forecast slightly lower from Q412, on account of READ MORE >

Executive Summary 6

SWOT Analysis 8

Slovakia Pharmaceuticals Industry SWOT 8

Slovakia Political SWOT 9

Slovakia Economic SWOT 9

Slovakia Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 11
Table: Central And Eastern Europe Pharmaceutical Risk/Rewards Ratings, Q113 11

Rewards 12

Risks 12

Slovakia - Market Summary 14

Regulatory Regime 15

Pharmaceutical Promotion and Advertising 16

Recent Regulatory Developments 17

Intellectual Property (IP) Regime 17

Pricing Regime 18
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 19

Reimbursement Regime 20

Pricing And Reimbursement Developments 21

Industry Trends And Developments 24

Epidemiology 24
Table: Main Causes Of Mortality And Morbidity In Slovakia 25

Communicable Diseases 25

Healthcare Sector 26

Recent Healthcare Sector Developments 27

Health Insurance 27

Private Health Insurance 29

Recent Health Insurance Developments 29

Research & Development 32

Biotechnology 32
Table: Members of BITCET, 2011 32
Table: Members SLOVBIOTECH, 2010 33

Clinical Trials 33

Medical Device Market 34
Table: EU Medical Devices Classifications 34

Industry Forecast Scenario 37

Pharmaceutical Market Forecast 37
Table: Pharmaceutical Sales, Historical Data and Forecasts 38

Healthcare Market Forecast 40
Table: Healthcare Expenditure Trends, Historical Data and Forecasts 41
Table: Government Healthcare Expenditure Trends, Historical Data and Forecasts 41
Table: Private Healthcare Expenditure Trends, Historical Data and Forecasts 42

Key Growth Factors - Macroeconomic 43
Table: Long-Term Macroeconomic Forecasts 44

Prescription Drug Market Forecast 45
Table: Leading OTC Medicines in Slovakia, by 2011 Volume- 46
Table: Prescription Drug Market Indicators, Historical Data and Forecasts 47

Patented Drug Market Forecast 48
Table: Patented Drug Market Indicators, Historical Data and Forecasts 49

Generic Drug Market Forecast 50
Table: Members of GENAS, 2011 52
Table: Generics Drug Market Indicators, Historical Data and Forecasts 52

OTC Medicine Market Forecast 53
Table: Leading Prescription Medicines in Slovakia, by 2011 Volume 54
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 55
Table: OTC Medicine Sales Breakdown, 2004-2009 55

Pharmaceutical Trade Forecast 57
Table: Pharmaceutical Trade Data And Forecasts (US$mn) 58
Table: Slovakia Pharmaceutical Trade Data And Forecasts (EURmn) 58

Medical Device Market Forecast 59
Table: Slovakia Medical Device Market Indicators, Historical Data and Forecasts 60

Other Healthcare Data Forecasts 61

Key Risks To BMI's Forecast Scenario 63

Competitive Landscape 64

Pharmaceutical Industry 64
Table: Registered Pharmaceutical Manufacturers 64

Members of SAFS, 2011 65

Pharmaceutical Distribution 66
Table: ADL Members, 2011 (Manufacturers, unless otherwise indicated) 67

Pharmaceutical Retail 67

Company Profiles 71

Local Companies 71

Zentiva (Sanofi) 71

Biotika 74

HBM Pharma (formerly Hoechst-Biotika) 76

Imuna Pharma 78

Multinational Companies 80

GlaxoSmithKline 80

Sanofi 81

Pfizer 83

Novartis 85

Merck & Co 86

Roche 87

Demographic Outlook 88
Table: Population By Age Group, 1990-2020 ('000) 89
Table: Population By Age Group, 1990-2020 (% of total) 90
Table: Key Population Ratios, 1990-2020 91
Table: Rural/Urban Population Split, 1990-2020 91

Glossary 92

BMI Methodology 94

How We Generate Our Pharmaceutical Industry Forecasts 94

Pharmaceutical Risk/Reward Ratings Methodology 95

Ratings Overview 95
Table: Pharmaceutical Business Environment Indicators 96

Weighting 97
Table: Weighting Of Components 97

Sources 97

Company Profiles
Local Companies
Zentiva (Sanofi)
Biotika
HBM Pharma (formerly Hoechst-Biotika)
Imuna Pharma
Multinational Companies
GlaxoSmithKline
Sanofi
Pfizer
Novartis
Merck & Co
Roche

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos